Effectiveness of 4 doses of COVID-19 vaccine in patients on maintenance hemodialysis in 5th wave of COVID-19 infection in Myanmar: Do we need 5 doses?
Main Article Content
Abstract
Background: Patients on maintenance hemodialysis (MHD) are at high risk of contracting SARS-CoV-2 and developing severe COVID-19 infection because they have low innate immunity as well as poor antibody response to COVID-19 vaccine. This study aimed to assess the effectiveness of 4 doses of COVID-19 vaccine in preventing 5th wave of COVID-19 infections in patients on maintenance hemodialysis in Myanmar.
Methods: A hospital-based descriptive study was conducted in July 2022 to November 2022 among patients on MHD who received COVID-19 vaccine 4 doses; last dose was 2 weeks ago. Data were collected by using standardized forms and analysis was done.
Results: A total of 61 patients on maintenance hemodialysis ( MHD) who had 4 doses of COVID-19 vaccination more than 2 weeks were included. Nasopharyngeal swab PCR was taken twice a week to all patients (if they did not have symptoms) and it was repeated if they had symptoms suggestive of COVID-19 infection or they had history of contact with patients having COVID-19 infection. Their signs and symptoms were analyzed; chest radiograph and blood tests were taken if indicated. Then, the severity of COVID-19 infection was determined according to WHO criteria and they were given treatment according to hospital guideline. They were followed up till 28 days.
The base line characteristics were as follows: mean age was 51.15 ± 12.85 years; male to female ratio was 4:6; mean BMI was 19.93 ± 2.83 kg/m2; 16.4%(10/61) had diabetic nephropathy; 9.8%(6/61) had cerebrovascular accident; 24.6%(15/61) had coronary heart disease; and one fifth of them were current smokers. Sixty six percent had past history of COVID-19 infection; duration from last infection was 404 days. Thirty three percent of cases had shortest duration of hemodialysis (6 months) and 23% were over 3 years. Mean duration from last vaccination was 39 days. Thirty six percent (22/61) had confirmed COVID-19 infection and 64% (39/61) of them were not infected till the end of 5th wave. All infected cases were mild form according to WHO criteria; none of them required oxygen therapy. One case having multiple comorbidities (lymphoma, coronary heart disease, hypertension and malignant cachexia) had sudden death due to pulmonary embolism.
Conclusions: The protection rate of four doses of COVID-19 vaccine in patients on MHD was not good as 36% of them were infected in the 5th wave of epidemic in Myanmar. However, all the infected cases were mild form and they did not need oxygen therapy showing that booster vaccination prevented morbidity and mortality. Therefore, the protection rate of four doses of COVID-19 vaccine in patients on MHD was nearly 65%; it reduced the severe form of infection and death. Fifth dose of COVID-19 vaccine is necessary along with personnel protective measures.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Akpolat, T. (2022). Reduced CoronaVac vaccine antibody response in patients with chronic kidney disease. International Urology and Nephrology, 54(6), 1459–1460. https://doi.org/10.1007/s11255-021-03023-1
II. Anand, S., Montez-Rath, M. E., Han, J., Garcia, P., Cadden, L., Hunsader, P., Kerschmann, R., Beyer, P., Dittrich, M., Block, G. A., Boyd, S. D., Parsonnet, J., & Chertow, G. M. (2021). Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. MedRxiv: The Preprint Server for Health Sciences, 2021.05.06.21256768. https://doi.org/10.1101/2021.05.06.21256768
III. Aoun, M., Kahwaji, R.-M., Sleilaty, G., Boueri, C., Hawi, J., Khalil, C. B., & Hage, V. (2022). Factors predictive of anti-spike antibody titers after COVID-19 vaccination in hemodialysis patients. Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University, 31(8), 855–861. https://doi.org/10.17219/acem/147360
IV. Ashby, D. R., Caplin, B., Corbett, R. W., Asgari, E., Kumar, N., Sarnowski, A., Hull, R., Makanjuola, D., Cole, N., Chen, J., Nyberg, S., McCafferty, K., Zaman, F., Cairns, H., Sharpe, C., Bramham, K., Motallebzadeh, R., Anwari, K. J., Salama, A. D., & Banerjee, D. (2022). Severity of COVID-19 after Vaccination among Hemodialysis Patients. Clinical Journal of the American Society of Nephrology, 17(6), 843. https://doi.org/10.2215/CJN.16621221
V. Bates, T. A., McBride, S. K., Leier, H. C., Guzman, G., Lyski, Z. L., Schoen, D., Winders, B., Lee, J.-Y., Lee, D. X., Messer, W. B., Curlin, M. E., & Tafesse, F. G. (2022). Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology, 7(68), eabn8014.
https://doi.org/10.1126/sciimmunol.abn8014
VI. Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki, M., Barkati, S., Fafard, J., Talbot, D., Gilca, V., Deceuninck, G., Garenc, C., Carignan, A., De Wals, P., & De Serres, G. (2022). Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada. JAMA Network Open, 5(10), e2236670–e2236670. https://doi.org/10.1001/jamanetworkopen.2022.36670
VII. Chimon, A., Ferrière, E., Lammouchi, M. A., Jouan, N., Michel, P.-A., Saloum, K., Morand-Joubert, L., Schnuriger, A., Leruez-Ville, M., Fourgeaud, J., Dahmane, D., Bentaarit, B., Guéry, B., Fessi, H., Kazdaghli, H., Sounni, F., Fearon, T., Boudhabhay, I., Pawlotsky, J.-M., … Sakhi, H. (2022). Presentation and outcomes of SARS-CoV-2 Omicron variant infection in haemodialysis patients. Clinical Kidney Journal, 15(9), 1785–1788. https://doi.org/10.1093/ckj/sfac137
VIII. Chu, D.-T., Vu Ngoc, S.-M., Vu Thi, H., Nguyen Thi, Y.-V., Ho, T.-T., Hoang, V.-T., Singh, V., & Al-Tawfiq, J. A. (2022). COVID-19 in Southeast Asia: Current status and perspectives. Bioengineered, 13(2), 3797–3809.
https://doi.org/10.1080/21655979.2022.2031417
IX. Demiray, A., Kanbay, A., & Kanbay, M. (2022). Long-term effect of COVID-19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely? Clinical Kidney Journal, 15(3), 369–371.
https://doi.org/10.1093/ckj/sfab265
X. Drakesmith, H., Pasricha, S.-R., Cabantchik, I., Hershko, C., Weiss, G., Girelli, D., Stoffel, N., Muckenthaler, M. U., Nemeth, E., Camaschella, C., Klenerman, P., & Zimmermann, M. B. (2021). Vaccine efficacy and iron deficiency: An intertwined pair? The Lancet. Haematology, 8(9), e666–e669.
https://doi.org/10.1016/S2352-3026(21)00201-5
XI. Eggink, D., Andeweg, S. P., Vennema, H., van Maarseveen, N., Vermaas, K., Vlaemynck, B., Schepers, R., van Gageldonk-Lafeber, A. B., van den Hof, S., Reusken, C. B., & Knol, M. J. (2022). Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 27(4).
https://doi.org/10.2807/1560-7917.ES.2022.27.4.2101196
XII. El Karoui, K., Hourmant, M., Ayav, C., Glowacki, F., Couchoud, C., & Lapidus, N. (2022). Vaccination and COVID-19 Dynamics in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 17(3), 395–402.
https://doi.org/10.2215/CJN.10300721
XIII. Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L. S., Ash, N., Alroy-Preis, S., Huppert, A., & Milo, R. (2022). Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. New England Journal of Medicine, 386(23), 2201–2212.
https://doi.org/10.1056/NEJMoa2118946
XIV. Grewal, R., Kitchen, S. A., Nguyen, L., Buchan, S. A., Wilson, S. E., Costa, A. P., & Kwong, J. C. (2022). Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: Test negative design study. BMJ, 378, e071502. https://doi.org/10.1136/bmj-2022-071502
XV. Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J., Munro, K., Cole, M., Tranquillini, C., Taylor-Kerr, A., Hettiarachchi, N., Calbraith, D., Sajedi, N., Milligan, I., Themistocleous, Y., Corrigan, D., Cromey, L., … Hopkins, S. (2022). Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. New England Journal of Medicine, 386(13), 1207–1220.
https://doi.org/10.1056/NEJMoa2118691
XVI. Islam, M., Ozturk, Y., & Koc, Y. (2021). Clinical outcomes of COVID-19 in hemodialysis patients in the city of Zonguldak, Turkey. International Urology and Nephrology, 53(7), 1445–1452. https://doi.org/10.1007/s11255-020-02781-8
XVII. Joung, S. Y., Ebinger, J. E., Sun, N., Liu, Y., Wu, M., Tang, A. B., Prostko, J. C., Frias, E. C., Stewart, J. L., Sobhani, K., & Cheng, S. (2022). Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity. JAMA Network Open, 5(8), e2227241–e2227241. https://doi.org/10.1001/jamanetworkopen.2022.27241
XVIII. Khin Phyu Pyar, Thurein Win, Aung Phyoe Kyaw, Zar Ni Htet Aung, Nyan Lin Maung,et al. (2022). J. Clinical Research and Reports, 11(5) DOI:10.31579/2690-1919 /262
XIX. Kocak, S. Y., Kayalar, A. O., Karaosmanoglu, H. K., & Yilmaz, M. (2021). COVID-19 in hemodialysis patients: A single-center experience in Istanbul. International Urology and Nephrology, 53(11), 2385–2397.
https://doi.org/10.1007/s11255-021-02823-9
XX. Lin, D.-Y., Gu, Y., Xu, Y., Zeng, D., Wheeler, B., Young, H., Sunny, S. K., & Moore, Z. (2022). Effects of Vaccination and Previous Infection on Omicron Infections in Children. New England Journal of Medicine, 387(12), 1141–1143.
https://doi.org/10.1056/NEJMc2209371
XXI. Malhotra, S., Mani, K., Lodha, R., Bakhshi, S., Mathur, V. P., Gupta, P., Kedia, S., Sankar, M. J., Kumar, P., Kumar, A., H, V., Ahuja, V., Sinha, S., Guleria, R., Dua, A., Ahmad, S., Upadhyay, A. D., Sati, H. C., Mani, K., … Pandit, S. (2022). COVID-19 infection, and reinfection, and vaccine effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi, India. The Lancet Regional Health - Southeast Asia, 3, 100023. https://doi.org/10.1016/j.lansea.2022.100023
XXII. Matsunami, M., Suzuki, T., Fukuda, J., Terao, T., Ukai, K., Sugihara, S., Toishi, T., Nagaoka, K., Nakata, M., Ohara, M., Yashima, J., Kuji, H., & Matsue, K. (2022). Comparison of antibody response following the second dose of SARS-CoV-2 mRNA vaccine in elderly patients with late-stage chronic kidney disease. Renal Replacement Therapy, 8(1), 13. https://doi.org/10.1186/s41100-022-00402-x
XXIII. MOHS. (2021). Coronavirus Disease 2019 (COVID-19) Surveillance Dashboard (Myanmar). https://mohs.gov.mm/Main/content/publication/2019-ncov
XXIV. Nobis, C. C., Dubeau Laramée, G., Kervezee, L., Maurice De Sousa, D., Labrecque, N., & Cermakian, N. (2019). The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways. Proceedings of the National Academy of Sciences, 116(40), 20077–20086.
https://doi.org/10.1073/pnas.1905080116
XXV. Park, J.-S., Minn, D., Hong, S., Jeong, S., Kim, S., Lee, C. H., & Kim, B. (2022). Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy. J Korean Med Sci, 37(23).
https://doi.org/10.3346/jkms.2022.37.e180
XXVI. Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R., & Ioannidis, J. P. A. (2022). SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environmental Research, 209, 112911.
https://doi.org/10.1016/j.envres.2022.112911
XXVII. Preston, A. E., Drakesmith, H., & Frost, J. N. (2021). Adaptive immunity and vaccination – iron in the spotlight. Immunotherapy Advances, 1(1), ltab007. https://doi.org/10.1093/immadv/ltab007
XXVIII. Pyar, K. P. (2022a). Initial presenting symptoms andseverity of SARS-CoV-2 Wild type, theDelta variant and the Omicron variant infected cases in early fourth wave ofepidemics in Myanmar. Research Review.
https://doi.org/10.52845/JMRHS/2022-5-1-8
XXIX. Pyar, K. P. (2022b). Breakthrough covid-19 infections among health care workers and their family members in fourth wave of pandemic in myanmar: Is third dose enough? Journal of Clinical Research and Reports, 11(5), 01–08.
https://doi.org/10.31579/2690-1919/262
XXX. Pyar, K. P., Kyaw, A. P., Maung, N. L., Aung, Z. N. H., Shan, M. A., Ya, K. Z., & Aung, A. (2022). Efficacy of Convalescent Plasma Therapy (CPT) plus Remdesivir versus Standard Therapy (Remdesivir) In Patients with Severe or Critical COVID-19 Infection in Second and Third Wave of Epidemics in Myanmar: Non-Randomized Interventional Study. Suntext Review Virology, 3(1). https://suntextreviews.org/doi/full/10.51737/2766-5003.2022.028
XXXI. Pyar, K. P., Wunna, K., Maung, N. L., Aung, Z. N. H., Aung, S. M., Win, T., Ya, K. Z., Kyaw, A. P., Kyaw, M. T., Aung, Z. P., Kyaw, A. H., Win, K. K., Min, W. K. K., & Tin, W. M. (2022). Breakthrough infections due to the Omicron variant of COVID-19 infection in Myanmar in June 2022: The value of surveillance and early quarantine to prevent fifth wave. International Journal Of Medical Science And Clinical Research Studies, 2(6), 555–561. https://doi.org/10.47191/ijmscrs/v2-i6-21
XXXII. Rincon-Arevalo, H., Choi, M., Stefanski, A.-L., Halleck, F., Weber, U., Szelinski, F., Jahrsdörfer, B., Schrezenmeier, H., Ludwig, C., Sattler, A., Kotsch, K., Potekhin, A., Chen, Y., Burmester, G. R., Eckardt, K.-U., Guerra, G. M., Durek, P., Heinrich, F., Ferreira-Gomes, M., … Dörner, T. (2021). Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Science Immunology, 6(60), eabj1031. https://doi.org/10.1126/sciimmunol.abj1031
XXXIII. Salerno, S., Messana, J. M., Gremel, G. W., Dahlerus, C., Hirth, R. A., Han, P., Segal, J. H., Xu, T., Shaffer, D., Jiao, A., Simon, J., Tong, L., Wisniewski, K., Nahra, T., Padilla, R., Sleeman, K., Shearon, T., Callard, S., Yaldo, A., … Li, Y. (2021). COVID-19 Risk Factors and Mortality Outcomes Among Medicare Patients Receiving Long-term Dialysis. JAMA Network Open, 4(11), e2135379–e2135379. https://doi.org/10.1001/jamanetworkopen.2021.35379
XXXIV. Sanders, J. S. F., Lianne Messchendorp, A., de Vries, R. D., Baan, C. C., van Baarle, D., van Binnendijk, R., Diavatopoulos, D. A., Geers, D., Schmitz, K. S., van Kessel, C. H. G., Hartog, G. den, Kho, M. M., Koopmans, M. P., van der Molen, R. G., Remmerswaal, E. B., Rots, N., Gansevoort, R. T., Bemelman, F. J., Hilbrands, L. B., & Reinders, M. E. (2022). Antibody and T-cell responses 6 months after COVID-19 mRNA-1273 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
https://doi.org/10.1093/cid/ciac557
XXXV. Šmíd, M., Berec, L., Přibylová, L., Májek, O., Pavlík, T., Jarkovský, J., Weiner, J., Barusová, T., & Trnka, J. (2022). Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of Infectious Diseases, 226(8), 1385–1390. https://doi.org/10.1093/infdis/jiac161
XXXVI. Spensley, K. J., Gleeson, S., Martin, P., Thomson, T., Clarke, C. L., Pickard, G., Thomas, D., McAdoo, S. P., Randell, P., Kelleher, P., Bedi, R., Lightstone, L., Prendecki, M., & Willicombe, M. (2022). Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. Kidney International Reports, 7(6), 1406–1409. https://doi.org/10.1016/j.ekir.2022.04.005
XXXVII. Thakur, V., & Ratho, R. K. (2022). OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. Journal of Medical Virology, 94(5), 1821–1824.
https://doi.org/10.1002/jmv.27541
XXXVIII. Wang, L., Li, J., Gao, Y., Li, R., Zhang, J., Su, D., Wang, T., Yang, G., & Wang, X. (2019). Association between coronary dominance and acute inferior myocardial infarction: A matched, case-control study. BMC Cardiovascular Disorders, 19(1), 35. https://doi.org/10.1186/s12872-019-1007-5
XXXIX. Yu, Y., Esposito, D., Kang, Z., Lu, J., Remaley, A. T., De Giorgi, V., Chen, L. N., West, K., & Cao, L. (2022). MRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Scientific Reports, 12(1), 2628.